On October 8, HANSOH PHARMA fell 3.01% in regular trading, trading at 32.84 HKD/share, with Turnover of 1.98 billion HKD.

The decline was driven by concurrent stake reductions by multiple entities linked to major shareholder Cen Junda, alongside the lingering impact from the European Commission's revocation of the marketing authorization for Aumolertinib. Disclosure records show that on October 2, Cantrust (Far East) Limited and related parties APEX MEDICAL COMPANY LTD., JQC Holding Limited, JQC International Limited, and Cen Junda each sold 124,000 shares at an average price of 33.9623 HKD, totaling approximately 4.21 million HKD. Although the reduction amount is limited, the synchronized action drew market attention. Earlier, the company confirmed that the EU marketing authorization for Aumolertinib was revoked due to procedural issues, and it plans to challenge the decision and resubmit a new application based on the original data package.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)